Edwards Lifesciences
720 hedge funds and large institutions have $20.8B invested in Edwards Lifesciences in 2017 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 227 increasing their positions, 287 reducing their positions, and 52 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 7 → 14 (+7)
67% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 52
25% more capital invested
Capital invested by funds: $16.6B → $20.8B (+$4.22B)
4% more funds holding
Funds holding: 690 → 720 (+30)
2.64% more ownership
Funds ownership: 249.22% → 251.86% (+2.6%)
21% less repeat investments, than reductions
Existing positions increased: 227 | Existing positions reduced: 287
33% less call options, than puts
Call options by funds: $62.5M | Put options by funds: $93.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$359M |
| 2 |
ECU
Egerton Capital (UK)
London,
United Kingdom
|
+$202M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$95.9M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$66.6M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$55.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$151M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$99.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$78.7M |
| 4 |
FAM
Fred Alger Management
New York
|
-$62.8M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$56.5M |
EW Hedge Fund Activity: Q2 2017 in Review
720 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2017, worth a combined $20.8B — up 25% from $16.6B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new EW positions and 52 closed out — a net gain of 35 holders — while 227 added to existing stakes and 287 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $359M. The largest seller was Ameriprise, cutting an estimated $151M.
- 720 institutional investors held Edwards Lifesciences (EW) as of Q2 2017, up from 690 in Q1 2017.
- Funds reported $20.8B of Edwards Lifesciences stock for Q2 2017, up 25% quarter-over-quarter.
- 87 funds opened new Edwards Lifesciences positions in Q2 2017 and 52 closed out, a net change of +35 holders.
- The largest Edwards Lifesciences buyer in Q2 2017 was Bank of New York Mellon, an estimated $359M added.
- The largest Edwards Lifesciences seller in Q2 2017 was Ameriprise, an estimated $151M sold.
Based on aggregated 13F filings for Q2 2017.